128 related articles for article (PubMed ID: 37807322)
1. STAT3 promotes migration and invasion of cholangiocarcinoma arising from choledochal cyst by transcriptionally inhibiting miR200c through the c-myb/MEK/ERK signaling pathway.
Liu W; Fan L; Shao B; Zhang Y
Cell Mol Biol (Noisy-le-grand); 2023 Sep; 69(9):136-142. PubMed ID: 37807322
[TBL] [Abstract][Full Text] [Related]
2. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.
Zheng T; Hong X; Wang J; Pei T; Liang Y; Yin D; Song R; Song X; Lu Z; Qi S; Liu J; Sun B; Xie C; Pan S; Li Y; Luo X; Li S; Fang X; Bhatta N; Jiang H; Liu L
Hepatology; 2014 Mar; 59(3):935-46. PubMed ID: 24037855
[TBL] [Abstract][Full Text] [Related]
3. Clonorchis sinensis granulin promotes malignant transformation of human intrahepatic biliary epithelial cells through interaction with M2 macrophages via regulation of STAT3 phosphorylation and the MEK/ERK pathway.
He Q; Pan X; Yin Y; Xu A; Yi X; Wu Y; Li X
Parasit Vectors; 2023 Apr; 16(1):139. PubMed ID: 37095578
[TBL] [Abstract][Full Text] [Related]
4. Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell.
Huang M; Huang B; Li G; Zeng S
BMC Gastroenterol; 2018 Nov; 18(1):169. PubMed ID: 30400838
[TBL] [Abstract][Full Text] [Related]
5. Allicin Inhibits Proliferation and Invasion in Vitro and in Vivo via SHP-1-Mediated STAT3 Signaling in Cholangiocarcinoma.
Chen H; Zhu B; Zhao L; Liu Y; Zhao F; Feng J; Jin Y; Sun J; Geng R; Wei Y
Cell Physiol Biochem; 2018; 47(2):641-653. PubMed ID: 29794468
[TBL] [Abstract][Full Text] [Related]
6. FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling.
Lu Z; Wang J; Zheng T; Liang Y; Yin D; Song R; Pei T; Pan S; Jiang H; Liu L
BMC Cancer; 2014 Oct; 14():783. PubMed ID: 25344679
[TBL] [Abstract][Full Text] [Related]
7. Enhanced expression of suppresser of cytokine signaling 3 inhibits the IL-6-induced epithelial-to-mesenchymal transition and cholangiocarcinoma cell metastasis.
Zhou QX; Jiang XM; Wang ZD; Li CL; Cui YF
Med Oncol; 2015 Apr; 32(4):105. PubMed ID: 25744243
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
Blechacz BR; Smoot RL; Bronk SF; Werneburg NW; Sirica AE; Gores GJ
Hepatology; 2009 Dec; 50(6):1861-70. PubMed ID: 19821497
[TBL] [Abstract][Full Text] [Related]
9. Myricetin ameliorates cytokine-induced migration and invasion of cholangiocarcinoma cells via suppression of STAT3 pathway.
Tuponchai P; Kukongviriyapan V; Prawan A; Kongpetch S; Senggunprai L
J Cancer Res Ther; 2019; 15(1):157-163. PubMed ID: 30880773
[TBL] [Abstract][Full Text] [Related]
10. High glucose enhances progression of cholangiocarcinoma cells via STAT3 activation.
Saengboonmee C; Seubwai W; Pairojkul C; Wongkham S
Sci Rep; 2016 Jan; 6():18995. PubMed ID: 26743134
[TBL] [Abstract][Full Text] [Related]
11. Terminal fucose mediates progression of human cholangiocarcinoma through EGF/EGFR activation and the Akt/Erk signaling pathway.
Indramanee S; Sawanyawisuth K; Silsirivanit A; Dana P; Phoomak C; Kariya R; Klinhom-On N; Sorin S; Wongkham C; Okada S; Wongkham S
Sci Rep; 2019 Nov; 9(1):17266. PubMed ID: 31754244
[TBL] [Abstract][Full Text] [Related]
12. Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway.
Sun R; Liu Z; Qiu B; Chen T; Li Z; Zhang X; Xu Y; Zhang Z
EBioMedicine; 2019 Sep; 47():142-155. PubMed ID: 31492557
[TBL] [Abstract][Full Text] [Related]
13. STATs profiling reveals predominantly-activated STAT3 in cholangiocarcinoma genesis and progression.
Dokduang H; Techasen A; Namwat N; Khuntikeo N; Pairojkul C; Murakami Y; Loilome W; Yongvanit P
J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):767-76. PubMed ID: 25044480
[TBL] [Abstract][Full Text] [Related]
14. Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors.
Ewald F; Nörz D; Grottke A; Hofmann BT; Nashan B; Jücker M
Invest New Drugs; 2014 Dec; 32(6):1144-54. PubMed ID: 25152244
[TBL] [Abstract][Full Text] [Related]
15. Luteolin arrests cell cycling, induces apoptosis and inhibits the JAK/STAT3 pathway in human cholangiocarcinoma cells.
Aneknan P; Kukongviriyapan V; Prawan A; Kongpetch S; Sripa B; Senggunprai L
Asian Pac J Cancer Prev; 2014; 15(12):5071-6. PubMed ID: 24998588
[TBL] [Abstract][Full Text] [Related]
16. Low Dose Berberine Suppresses Cholangiocarcinoma Cell Progression as a Multi-Kinase Inhibitor.
Obchoei S; Detarya M; Boonnate P; Saranaruk P; Vaeteewoottacharn K; Mahalapbutr P; Okada S; Wongkham S
Asian Pac J Cancer Prev; 2022 Oct; 23(10):3379-3386. PubMed ID: 36308362
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of TTYH3 promotes epithelial-to-mesenchymal transition through Wnt/β-catenin signaling and inhibits apoptosis in cholangiocarcinoma.
Xue W; Dong B; Zhao Y; Wang Y; Yang C; Xie Y; Niu Z; Zhu C
Cell Oncol (Dordr); 2021 Dec; 44(6):1351-1361. PubMed ID: 34796468
[TBL] [Abstract][Full Text] [Related]
18. Syndecan-1 suppresses cell growth and migration via blocking JAK1/STAT3 and Ras/Raf/MEK/ERK pathways in human colorectal carcinoma cells.
Wang S; Zhang X; Wang G; Cao B; Yang H; Jin L; Cui M; Mao Y
BMC Cancer; 2019 Nov; 19(1):1160. PubMed ID: 31783811
[TBL] [Abstract][Full Text] [Related]
19. MCM2 promotes the proliferation, migration and invasion of cholangiocarcinoma cells by reducing the p53 signaling pathway.
Wang CL; Liu XY; Wang YH; Zhang Z; Wang ZD; Zhou GQ
Yi Chuan; 2022 Mar; 44(3):230-244. PubMed ID: 35307646
[TBL] [Abstract][Full Text] [Related]
20. Adaptor protein XB130 regulates the aggressiveness of cholangiocarcinoma.
Poosekeaw P; Pairojkul C; Sripa B; Sa Ngiamwibool P; Iamsaard S; Sakonsinsiri C; Thanan R; Ungarreevittaya P
PLoS One; 2021; 16(11):e0259075. PubMed ID: 34780466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]